131 related articles for article (PubMed ID: 18585815)
1. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.
Wada T; Azegami M; Sugiyama M; Tsuneki H; Sasaoka T
Diabetes Res Clin Pract; 2008 Sep; 81(3):269-77. PubMed ID: 18585815
[TBL] [Abstract][Full Text] [Related]
2. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
3. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.
Weinstein D; Simon M; Yehezkel E; Laron Z; Werner H
Diabetes Metab Res Rev; 2009 Jan; 25(1):41-9. PubMed ID: 19145584
[TBL] [Abstract][Full Text] [Related]
4. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
5. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157
[TBL] [Abstract][Full Text] [Related]
6. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
Heise T; Pieber TR
Diabetes Obes Metab; 2007 Sep; 9(5):648-59. PubMed ID: 17645556
[TBL] [Abstract][Full Text] [Related]
7. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.
Ciaraldi TP; Carter L; Seipke G; Mudaliar S; Henry RR
J Clin Endocrinol Metab; 2001 Dec; 86(12):5838-47. PubMed ID: 11739448
[TBL] [Abstract][Full Text] [Related]
8. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
9. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
Fink H; Herbert C; Gilor C
Domest Anim Endocrinol; 2018 Jul; 64():17-30. PubMed ID: 29709796
[TBL] [Abstract][Full Text] [Related]
14. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
[TBL] [Abstract][Full Text] [Related]
15. Tissue selectivity of insulin detemir action in vivo.
Hennige AM; Sartorius T; Tschritter O; Preissl H; Fritsche A; Ruth P; Häring HU
Diabetologia; 2006 Jun; 49(6):1274-82. PubMed ID: 16570163
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.
Gilor C; Ridge TK; Attermeier KJ; Graves TK
J Vet Intern Med; 2010; 24(4):870-4. PubMed ID: 20561185
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
20. Insulin analogues.
Marks J
Postgrad Med; 2002 Nov; 112(5 Suppl Designer):8-12. PubMed ID: 19667599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
